Quarterly ResultAug 4, 2026, 06:08 AM
Lipocine Q2 Net Loss $(2.62)M; Raises $13.47M via ATM Offering
AI Summary
Lipocine Inc. reported a net loss of $2.62 million for Q2 2026, an increase from $2.21 million in Q2 2025, with total revenues decreasing to $0.19 million. For the first six months of 2026, the net loss widened to $6.29 million. The company significantly strengthened its financial position by raising $13.47 million through an At-The-Market (ATM) offering and received marketing authorization for TESTYRA® (TLANDO) in the UAE.
Key Highlights
- Q2 2026 net loss was $(2.62) million, compared to $(2.21) million in Q2 2025.
- H1 2026 net loss was $(6.29) million, compared to $(4.07) million in H1 2025.
- Total revenues for Q2 2026 decreased to $0.19 million from $0.62 million in Q2 2025.
- Raised $13.47 million in net proceeds from an ATM offering during H1 2026.
- Cash and cash equivalents stood at $4.98 million as of June 30, 2026.
- Total stockholders' equity increased to $21.77 million as of June 30, 2026.
- Received marketing authorization for TESTYRA® (TLANDO) in the UAE on July 8, 2026.
- Believes capital resources are sufficient through at least August 4, 2027.
Price Impact
More from LPCN